88 related articles for article (PubMed ID: 28524099)
21. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
22. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.
Calero-Pérez P; Wu S; Arús C; Candiota AP
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071393
[TBL] [Abstract][Full Text] [Related]
23. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
24. Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition.
Segerman A; Niklasson M; Haglund C; Bergström T; Jarvius M; Xie Y; Westermark A; Sönmez D; Hermansson A; Kastemar M; Naimaie-Ali Z; Nyberg F; Berglund M; Sundström M; Hesselager G; Uhrbom L; Gustafsson M; Larsson R; Fryknäs M; Segerman B; Westermark B
Cell Rep; 2016 Dec; 17(11):2994-3009. PubMed ID: 27974212
[TBL] [Abstract][Full Text] [Related]
25. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
26. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
[TBL] [Abstract][Full Text] [Related]
27. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
28. Ki-67/MIB-1 immunostaining in a cohort of human gliomas.
Skjulsvik AJ; Mørk JN; Torp MO; Torp SH
Int J Clin Exp Pathol; 2014; 7(12):8905-10. PubMed ID: 25674263
[TBL] [Abstract][Full Text] [Related]
29. The evidence of glioblastoma heterogeneity.
Soeda A; Hara A; Kunisada T; Yoshimura S; Iwama T; Park DM
Sci Rep; 2015 Jan; 5():7979. PubMed ID: 25623281
[TBL] [Abstract][Full Text] [Related]
30. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
31. ¹H MRS characterization of neurochemical profiles in orthotopic mouse models of human brain tumors.
Hulsey KM; Mashimo T; Banerjee A; Soesbe TC; Spence JS; Vemireddy V; Maher EA; Bachoo RM; Choi C
NMR Biomed; 2015 Jan; 28(1):108-15. PubMed ID: 25394324
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
33. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
[TBL] [Abstract][Full Text] [Related]
34. Molecular heterogeneity of glioblastoma and its clinical relevance.
Eder K; Kalman B
Pathol Oncol Res; 2014 Oct; 20(4):777-87. PubMed ID: 25156108
[TBL] [Abstract][Full Text] [Related]
35. Trial Watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E; Aranda F; Eggermont A; Galon J; Sautès-Fridman C; Cremer I; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Jan; 3(1):e27878. PubMed ID: 24800173
[TBL] [Abstract][Full Text] [Related]
36. Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10.
Oborski MJ; Laymon CM; Qian Y; Lieberman FS; Nelson AD; Mountz JM
Transl Oncol; 2014 Feb; 7(1):111-9. PubMed ID: 24772214
[TBL] [Abstract][Full Text] [Related]
37. A novel semi-supervised methodology for extracting tumor type-specific MRS sources in human brain data.
Ortega-Martorell S; Ruiz H; Vellido A; Olier I; Romero E; Julià-Sapé M; Martín JD; Jarman IH; Arús C; Lisboa PJ
PLoS One; 2013; 8(12):e83773. PubMed ID: 24376744
[TBL] [Abstract][Full Text] [Related]
38. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.
Stieber D; Golebiewska A; Evers L; Lenkiewicz E; Brons NH; Nicot N; Oudin A; Bougnaud S; Hertel F; Bjerkvig R; Vallar L; Barrett MT; Niclou SP
Acta Neuropathol; 2014 Feb; 127(2):203-19. PubMed ID: 24154962
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
